{"id":4719,"date":"2023-10-02T21:27:50","date_gmt":"2023-10-02T12:27:50","guid":{"rendered":"https:\/\/www.aureo.co.jp\/?p=4719"},"modified":"2023-10-03T17:03:41","modified_gmt":"2023-10-03T08:03:41","slug":"5242855","status":"publish","type":"post","link":"https:\/\/www.aureo.co.jp\/en\/patent\/5242855\/","title":{"rendered":"Immune adjuvant &#8211; Japan (Patent No. 5242855)"},"content":{"rendered":"<p><img loading=\"lazy\" decoding=\"async\" class=\"aligncenter size-medium\" style=\"font-size: 16px;\" src=\"https:\/\/www.aureo.co.jp\/wp-content\/uploads\/2020\/07\/JapanTokkyo5242855-1.png\" width=\"496\" height=\"702\" \/><\/p>\n<p class=\"Blue_Sub\">Patent Details<\/p>\n<div>\n<dl class=\"tbl\">\n<dt>\n<div>Patent No.<\/div>\n<\/dt>\n<dd>No. 5242855<\/dd>\n<\/dl>\n<dl class=\"tbl\">\n<dt>\n<div>Registration Date<\/div>\n<\/dt>\n<dd>April 12, 2013<\/dd>\n<\/dl>\n<\/div>\n<p>Aureobasidium (black yeast) culture medium (hereafter referred to as &#8220;Aureo culture medium&#8221;) was tested as an &#8220;adjuvant&#8221; substance to further enhance the efficacy of the intranasal vaccine.<\/p>\n<p>The group that received the intranasal vaccine alone showed higher antibody titers for both IgA and IgG than the group that received the intranasal vaccine in combination with the Aureo culture medium.<\/p>\n<p>These results indicate that Aureo culture medium has an adjuvant effect for intranasal vaccines.<\/p>\n<p><Terminology><br \/>\nAdjuvant: A substance that aids or enhances the effect of a vaccine.<br \/>\nIgA: Antibody that exists in large quantities in mucous membranes<br \/>\nIgG: Antibody that exists in large quantities in the serum<\/p>\n<!-- AddThis Advanced Settings generic via filter on the_content --><!-- AddThis Share Buttons generic via filter on the_content -->","protected":false},"excerpt":{"rendered":"<p>Patent Details Patent No. No. 5242855 Registration Date April 12, 2013 Aureobasidium (black yeast) culture medium (hereafter referred to as &#8220;Aureo culture medium&#8221;) was tested as an &#8220;adjuvant&#8221; substance to further enhance the efficacy of the intranasal vaccine. The group<!-- AddThis Advanced Settings generic via filter on get_the_excerpt --><!-- AddThis Share Buttons generic via filter on get_the_excerpt --><\/p>\n","protected":false},"author":6,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_locale":"en_US","_original_post":"https:\/\/www.aureo.co.jp\/?p=4092","footnotes":""},"categories":[9],"tags":[],"class_list":["post-4719","post","type-post","status-publish","format-standard","hentry","category-patent","en-US"],"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/www.aureo.co.jp\/wp-json\/wp\/v2\/posts\/4719","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.aureo.co.jp\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.aureo.co.jp\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.aureo.co.jp\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.aureo.co.jp\/wp-json\/wp\/v2\/comments?post=4719"}],"version-history":[{"count":2,"href":"https:\/\/www.aureo.co.jp\/wp-json\/wp\/v2\/posts\/4719\/revisions"}],"predecessor-version":[{"id":4851,"href":"https:\/\/www.aureo.co.jp\/wp-json\/wp\/v2\/posts\/4719\/revisions\/4851"}],"wp:attachment":[{"href":"https:\/\/www.aureo.co.jp\/wp-json\/wp\/v2\/media?parent=4719"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.aureo.co.jp\/wp-json\/wp\/v2\/categories?post=4719"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.aureo.co.jp\/wp-json\/wp\/v2\/tags?post=4719"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}